Expansion Momentum Niowave is actively expanding its Lansing footprint with a $75M radiopharmaceutical isotope facility and a $65M airport facility, signaling aggressive capacity growth and potential demand for advanced supply chain services, equipment, and commissioning support.

Strategic Partners Recent collaboration with Aptevo Therapeutics and a 10-year Ac-225 production agreement with AZ indicate a strong partner-led sales pathway for radiopharmaceuticals, radiochemistry services, and related regulatory support.

AdvancedTech Advantage The use of a superconducting linac to produce Actinium-225 avoids reactors and HEU, presenting a compelling value proposition for customers seeking safer, licensed-friendly isotope production solutions with scalable automation and streamlined licensing.

Regulatory Readiness Niowave’s alignment with FDA approval processes and existing radiopharmaceutical supply chains positions it to offer end-to-end solutions, enabling faster time-to-market for new radiopharmaceutical products and potential cross-sell of radiochemistry automation.

Market Interest With revenue in the range of fifty to one hundred million and ongoing national expansion, there is appetite among pharmaceutical and biotech customers for reliable Ac-225 supply, radiopharmaceutical partnerships, and facilities-ready turnkey production services.